TG THERAPEUTICS, INC. (TGTX) Free cash flow 2016–2025
TG THERAPEUTICS, INC. (TGTX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$25.0MFY2025 · since FY2016: -$61.9M → -$25.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$25.0M | +38.4% |
| FY2024 | -$40.6M | -29.1% |
| FY2023 | -$31.4M | +82.2% |
| FY2022 | -$176.2M | +40.5% |
| FY2021 | -$296.0M | -37.8% |
| FY2020 | -$214.9M | -61.6% |
| FY2019 | -$132.9M | -3.0% |
| FY2018 | -$129.0M | -37.6% |
| FY2017 | -$93.8M | -51.4% |
| FY2016 | -$61.9M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More TGTX financial trends
TGTX RevenueTGTX Net incomeTGTX Net marginTGTX Gross profitTGTX Gross marginTGTX Operating incomeTGTX Operating marginTGTX Operating cash flowTGTX Capital expendituresTGTX Return on equityTGTX Stock buybacksTGTX Dividends paidTGTX Total assetsTGTX Total liabilitiesTGTX Shareholders’ equityTGTX overview →